RU2010107301A - METHOD FOR TREATMENT OF INFECTIOUS DISEASES CAUSED BY INFLUENZA VIRUS WITH TYPE OF SURFACE ANTIGEN H5N1, AND MEDICINE FOR TREATMENT OF INFECTIOUS DISEASES CAUSED BY HEROGRAPHY VIRGIN - Google Patents
METHOD FOR TREATMENT OF INFECTIOUS DISEASES CAUSED BY INFLUENZA VIRUS WITH TYPE OF SURFACE ANTIGEN H5N1, AND MEDICINE FOR TREATMENT OF INFECTIOUS DISEASES CAUSED BY HEROGRAPHY VIRGIN Download PDFInfo
- Publication number
- RU2010107301A RU2010107301A RU2010107301/15A RU2010107301A RU2010107301A RU 2010107301 A RU2010107301 A RU 2010107301A RU 2010107301/15 A RU2010107301/15 A RU 2010107301/15A RU 2010107301 A RU2010107301 A RU 2010107301A RU 2010107301 A RU2010107301 A RU 2010107301A
- Authority
- RU
- Russia
- Prior art keywords
- treatment
- infectious diseases
- diseases caused
- interferon
- active substance
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
1. Способ лечения и профилактики инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена H5N1, у человека, домашних животных и птиц, характеризующийся тем, что используют действующую субстанцию в виде гомеопатически активированной - потенцированной формы, полученной путем многократного последовательного разведения матричного раствора аффинно очищенных антител к гамма-интерферону человека и промежуточного внешнего воздействия. ! 2. Способ лечения по п.1, характеризующийся тем, что используют лекарственное средство, включающее смесь различных гомеопатических разведений. ! 3. Способ лечения по п.1, характеризующийся тем, что используют лекарственное средство, включающее смесь гомеопатических разведении С 12, С 30, С 50 или С 12, С 30, С 200. ! 4. Способ лечения по п.1, характеризующийся тем, что используют активированную - потенцированную форму действующей субстанции, которая получена из матричного раствора аффинно очищенных антител к гамма-интерферону человека с концентрацией 0,3÷5,0 мг/мл. ! 5. Лекарственное средство для лечения и профилактики инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена H5N1, характеризующийся тем, что включает действующую субстанцию в виде гомеопатически активированной - потенцированной формы аффинно очищенных антител к гамма-интерферону человека. ! 6. Лекарственное средство по п.5, характеризующееся тем, что гомеопатически активированная - потенцированная форма действующей субстанции получена из матричного раствора аффинно очищенных антител к гамма-интерферону человека с концентрацией 0,3÷5,0 мг/мл. ! 7. Лекарственное средство по п.5, хара 1. A method for the treatment and prevention of infectious diseases caused by influenza virus with the surface antigen type H5N1 in humans, domestic animals and birds, characterized in that the active substance is used in the form of a homeopathically activated potentiated form obtained by repeated serial dilution of the affinity purified matrix solution antibodies to human gamma interferon and intermediate external exposure. ! 2. The treatment method according to claim 1, characterized in that the use of a medicinal product, comprising a mixture of various homeopathic dilutions. ! 3. The treatment method according to claim 1, characterized in that a drug is used that includes a mixture of homeopathic dilutions of C 12, C 30, C 50 or C 12, C 30, C 200.! 4. The treatment method according to claim 1, characterized in that an activated - potentiated form of the active substance is used, which is obtained from a matrix solution of affinity-purified antibodies to human gamma-interferon with a concentration of 0.3 ÷ 5.0 mg / ml. ! 5. A drug for the treatment and prevention of infectious diseases caused by influenza virus with the type of surface antigen H5N1, characterized in that it comprises an active substance in the form of a homeopathically activated - potentiated form of affinity purified antibodies to human gamma-interferon. ! 6. The drug according to claim 5, characterized in that the homeopathically activated - potentiated form of the active substance is obtained from a matrix solution of affinity-purified antibodies to human gamma-interferon with a concentration of 0.3 ÷ 5.0 mg / ml. ! 7. The drug according to claim 5, hara
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2010107301/15A RU2500426C2 (en) | 2010-02-27 | 2010-02-27 | Method of treating infectious diseases caused by influenza virus with type h5n1 surface antigen and therapeutic agent for treating infectious diseases caused by influenza virus with type h5n1 surface antigen |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2010107301/15A RU2500426C2 (en) | 2010-02-27 | 2010-02-27 | Method of treating infectious diseases caused by influenza virus with type h5n1 surface antigen and therapeutic agent for treating infectious diseases caused by influenza virus with type h5n1 surface antigen |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2010107301A true RU2010107301A (en) | 2011-09-10 |
RU2500426C2 RU2500426C2 (en) | 2013-12-10 |
Family
ID=44757230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010107301/15A RU2500426C2 (en) | 2010-02-27 | 2010-02-27 | Method of treating infectious diseases caused by influenza virus with type h5n1 surface antigen and therapeutic agent for treating infectious diseases caused by influenza virus with type h5n1 surface antigen |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2500426C2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2682049C2 (en) * | 2014-01-27 | 2019-03-14 | Дженентек, Инк. | H7n9 influenza a therapy |
GB2566200A (en) | 2016-05-17 | 2019-03-06 | Iliich Epshtein Oleg | A pharmaceutical composition that includes a neutral carrier treated with energy and related methods of treatment |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2366697C2 (en) * | 2007-07-03 | 2009-09-10 | Закрытое Акционерное Общество "Дижафарм" | Agent of systemic action, its application, pharmaceutical compositions, methods of treatment and prevention |
CN101538327B (en) * | 2009-05-04 | 2011-07-06 | 中国疾病预防控制中心病毒病预防控制所 | Anthropogenic H5N1-resisting hemagglutinin protein broad-spectrum neutralising antibody and application thereof |
-
2010
- 2010-02-27 RU RU2010107301/15A patent/RU2500426C2/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2500426C2 (en) | 2013-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122291T1 (en) | INHIBITORS OF VIRAL REPLICATION | |
EA200701519A1 (en) | LIVE ATTENUATED ROTAVIRAL VACCINE FOR ORAL ADMINISTRATION | |
BR112012030641A2 (en) | methods and compositions for oral pharmaceutical therapy | |
ES2555557R1 (en) | Drug and use to prepare a drug for the prevention of HIV infection and the treatment of HIV-caused diseases, including AIDS | |
JP2013538195A5 (en) | ||
RU2010107301A (en) | METHOD FOR TREATMENT OF INFECTIOUS DISEASES CAUSED BY INFLUENZA VIRUS WITH TYPE OF SURFACE ANTIGEN H5N1, AND MEDICINE FOR TREATMENT OF INFECTIOUS DISEASES CAUSED BY HEROGRAPHY VIRGIN | |
EA200901064A1 (en) | DRUG FOR THE TREATMENT OF INFLUENZA IN BIRDS | |
RU2020120876A (en) | A PHARMACEUTICAL COMPOSITION CONTAINING ANTAGONIST OF MINERALOCORTICOID RECEPTORS AND ITS APPLICATION | |
RU2010107302A (en) | METHOD FOR TREATMENT OF INFECTIOUS DISEASES CAUSED BY INFLUENZA VIRUS WITH TYPE OF SURFACE ANTIGEN H1N1, AND MEDICINE FOR TREATMENT OF INFECTIOUS DISEASES CAUSED BY ANTI-VIRGIN | |
RU2011127226A (en) | METHOD FOR TREATING INFECTIOUS DISEASES AND AN INTEGRATED MEDICINE FOR THE TREATMENT OF INFECTIOUS DISEASES | |
EA201600364A1 (en) | 2-METHYLSULFANIL-6-NITRO-7-OXO-1,2,4-TRIAZOLO [5,1-C] [1,2,4] TRIAZINID L-ARGININIA DIHYDRATE, HAVING ACTIVITY, METHOD FOR ITS PREPARATION AND APPLICATION OF PREVENTION AND PREVENTION WESTERN NEIL FEVER | |
RU2010133053A (en) | INTEGRATED MEDICINE FOR TREATMENT OF VIRAL DISEASES AND METHOD OF TREATMENT OF VIRAL DISEASES | |
RU2010153722A (en) | METHOD FOR INCREASING EFFECTIVENESS OF TREATMENT OF HYPOFUNCTIONS OF OVARIES IN COWS | |
RU2014103224A (en) | METHOD FOR TREATING INFECTIOUS DISEASES CAUSED BY INFLUENZA VIRUS WITH TYPE OF SURFACE ANTIGEN H1N1 IN HOME ANIMALS AND BIRDS, AND MEDICINE FOR TREATMENT OF INFECTIOUS NOSE BREAST ANALYSIS | |
RU2010131386A (en) | MEDICINAL PRODUCT FOR TREATMENT OF INFECTIOUS DISEASES ASSOCIATED WITH NEUROTOXIC DISORDERS, AND METHOD FOR TREATMENT OF INFECTIOUS DISEASES ASSOCIATED WITH NEUROTOXIC DISEASES | |
RU2010107303A (en) | METHOD FOR IMPROVING ANTI-VIRAL ACTIVITY OF A MEDICINE BASED ON AN ACTIVELY ACTIVE SUBSTANCE OF OZELTAMIVIR | |
RU2011127056A (en) | MEDICINAL PRODUCT FOR TREATMENT OF PATHOLOGICAL SYNDROME AND METHOD FOR TREATING MULTIPLE SCLEROSIS | |
Grobler | Nano & micro-delivery systems: the Pheroid® story | |
RU2014139922A (en) | Infectious Disease Medication | |
AJAYKUMAR et al. | D. SATHIS KUMAR, DAVID BANJI, DAVID BANJI, DAVID BANJI, K. RAJASHEKAR, K. RAJASHEKAR, K. RAJASHEKAR, CH. RAHUL, CH. RAHUL, A. KRANTHI, A. KRANTHI, A. KRANTHI, M. ADARSH VERMA | |
RU2013152873A (en) | PHARMACEUTICAL COMPOSITION | |
Dong et al. | Yujie Dong, Ying Zhou, Xixia Chu, Shiqing Chen, Lei Chen, Beimeng Yang, Xu Zhang, Lin Wang, Shuai Wang, Jingyu Lou, Qing Deng, Li Wang, Zheyi Cao, Jianan Wang, Jiaxin Xie, Tatiana Serdyuk, Shengtian Li, Lin He, Xiaoping Chen, Weidong Li Dental noise exposed mice display depressive-like phenotypes | |
EA201892350A1 (en) | PREPARATION FOR INHALATION ON THE BASIS OF ISOGLYCYRRISINIC ACID OR ITS SALT AND ITS APPLICATION IN THE OBTAINING OF MEDICINES FOR TREATING DISEASES OF THE RESPIRATORY SYSTEM | |
TH104396B (en) | Prevention and treatment of PRDC | |
Passi | New in brief |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190228 |